Factors associated with disability in patients with ulcerative colitis: A cross-sectional study.
Adult
Aged
Aged, 80 and over
Chronic Disease
Colitis, Ulcerative
/ pathology
Cost of Illness
Cross-Sectional Studies
Disability Evaluation
Female
Humans
Male
Middle Aged
Prospective Studies
Quality of Life
Registries
Severity of Illness Index
Statistics, Nonparametric
Surveys and Questionnaires
Young Adult
disability
disease activity
fecal calprotectin
quality of life
ulcerative colitis
Journal
Journal of digestive diseases
ISSN: 1751-2980
Titre abrégé: J Dig Dis
Pays: Australia
ID NLM: 101302699
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
29
04
2019
revised:
13
12
2019
accepted:
16
12
2019
pubmed:
21
12
2019
medline:
10
10
2020
entrez:
21
12
2019
Statut:
ppublish
Résumé
Ulcerative colitis (UC) can give rise to several restrictions of patients' working and social activities. We aimed to determine the association between disease chronicity and the state of disability in a large population with UC. We recruited consecutive patients with UC attending the inflammatory bowel disease (IBD) unit of the Azienda Ospedaliera of Padua between July and December 2017. We collected patients' characteristics and clinical information, and all participants completed the IBD questionnaire (IBDQ) for quality of life assessment and the IBD disability index (IBD-DI) questionnaire. Using univariate logistic regression models we assessed whether the patients' characteristics and IBD-related variables were associated with an IBD-DI score ≤3.5. Statistically significant variables in the univariate analyses were then included in a multivariate regression model. Correlations between IBD-DI and all the above mentioned characteristics were investigated using the Spearman's rank correlation coefficient. We included 201 patients. A positive correlation was observed between IBD-DI and IBDQ (r = 0.82, P < 0.001). Multivariate regression modelling identified the following as independent factors related to disability: active disease (partial Mayo score ≥2) (odds ratio [OR] 6.54, 95% CI 3.21-13.22), the presence of extraintestinal manifestations (EIM) (OR 2.48, 95%, CI 1.11-5.54) and occasional alcohol consumption (OR 0.39, 95% CI 0.20-0.76). Impaired disability is mainly correlated with disease activity, the presence of EIM and no alcohol consumption. Moreover, there is a strong correlation with patients' quality of life. Therefore, in clinical practice, greater awareness of IBD-related disability is needed to better manage patients' outcomes.
Identifiants
pubmed: 31859432
doi: 10.1111/1751-2980.12837
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
81-87Subventions
Organisme : Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
Informations de copyright
© 2019 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.
Références
Bannaga AS, Selinger CP. Inflammatory bowel disease and anxiety: links, risks, and challenges faced. Clin Exp Gastroenterol. 2015;8:111-117. https://doi.org/10.2147/CEG.S57982.
Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504-1517.
Leong RWL, Huang T, Ko Y, et al. Prospective validation study of the International Classification of Functioning, Disability and Health score in Crohn's disease and ulcerative colitis. J Crohns Colitis. 2014;8(10):1237-1245.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785-1794.
Colombel JF. Measuring disability in IBD: the IBD disability index. Gastroenterol Hepatol. 2013;9(5):300-302.
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324-1338.
Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 1992;14(1):15-19.
Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989;96(3):804-810.
Smith GD, Watson R, Palmer KR. Inflammatory bowel disease: developing a short disease specific scale to measure health related quality of life. Int J Nurs Stud. 2002;39(6):583-590.
Garrett JW, Drossman DA. Health status in inflammatory bowel disease. Biological and behavioral considerations. Gastroenterology. 1990;99(1):90-96.
Casellas F, López-Vivancos J, Vergara M, Malagelada J. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis. 1999;17(4):208-218.
Palm Ø, Bernklev T, Moum B, Gran JT. Non-inflammatory joint pain in patients with inflammatory bowel disease is prevalent and has a significant impact on health related quality of life. J Rheumatol. 2005;32(9):1755-1759.
World Health Organization. International Classification of Functioning, Disability and Health (ICF) Geneva World Health Organization; 2001.
Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the International Classification of Functioning, Disability and Health. Gut. 2012;61(2):241-247.
Peyrin-Biroulet L. What is the patient's perspective: how important are patient-reported outcomes, quality of life and disability? Dig Dis. 2010;28(3):463-471.
Gower-Rousseau C, Sarter H, Savoye G, et al. Validation of the inflammatory bowel disease disability index in a population-based cohort. Gut. 2017;66(4):588-596.
Vergara M, Sicilia B, Prieto L, et al. Development and validation of the short Crohnʼs disease work disability questionnaire. Inflamm Bowel Dis. 2016;22(4):955-962.
Soares JB, Pereira R, Costa JM, Arroja B, Gonçalves R. The inflammatory bowel disease-disability index: validation of the Portuguese version according to the COSMIN checklist. Eur J Gastroenterol Hepatol. 2016;28(10):1151-1160.
van Der Have M, Fidder HH, Leenders M, et al. Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis. 2015;21(2):369-377.
Lee Y, McCombie A, Gearry R, et al. Disability in restorative proctocolectomy recipients measured using the inflammatory bowel disease disability index. J Crohns Colitis. 2016;10(12):1378-1384.
Chan W, Shim HH, Lim MS, et al. Symptoms of anxiety and depression are independently associated with inflammatory bowel disease-related disability. Dig Liver Dis. 2017;49(12):1314-1319.
van der List E, Chen A, Leong R, et al. Disability in surgical inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2017;15(1):157-158.
Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012;6(10):965-990.
Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-753.
Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43(1):29-32.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomization study. N Engl J Med. 1987;317(26):1625-1629.
Falvey JD, Hoskin T, Meijer B, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21(4):824-831.
Ciccocioppo R, Klersy C, Russo ML, et al. Validation of the Italian translation of the inflammatory bowel disease questionnaire. Dig Liver Dis. 2011;43(7):535-541.
Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106(2):287-296.
Mitchell A, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol. 1988;10(3):306-310.
Harbord M, Annese V, Vavricka SR, et al. The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2016;10(3):239-254.
Vavricka SR, Brun L, Ballabeni P, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110-119.
Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol. 1996;23(1):29-34.
Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9(3):211-222.
Crawford J. Anemia and lung cancer. Lung Cancer. 2002;38(Suppl):75-78.
Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7(11):599-610.
Befrits R, Wikman O, Blomquist L, et al. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life. Scand J Gastroenterol. 2013;48(9):1027-1032.